Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
EVH

EVH - Evolent Health Inc Stock Price, Fair Value and News

34.07USD+4.30 (+14.44%)Market Closed
Watchlist

Market Summary

USD34.07+4.30
Market Closed
14.44%

EVH Alerts

  • JPMORGAN CHASE & CO reported owning 5.1% of EVH [2024-01-18]
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

EVH Stock Price

View Fullscreen

EVH RSI Chart

EVH Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-32.82

Price/Sales (Trailing)

1.99

EV/EBITDA

-173.17

Price/Free Cashflow

36.58

EVH Price/Sales (Trailing)

EVH Profitability

Operating Margin

23.45%

EBT Margin

-10.31%

Return on Equity

-11.18%

Return on Assets

-4.45%

Free Cashflow Yield

2.73%

EVH Fundamentals

EVH Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

45.4%

Rev. Growth (Qtr)

8.81%

EVH Earnings

Earnings (TTM)

-119.3M

Earnings Growth (Yr)

-194.4%

Earnings Growth (Qtr)

-31.93%

Breaking Down EVH Revenue

Last 7 days

0.8%

Last 30 days

-1.7%

Last 90 days

5.5%

Trailing 12 Months

-4.5%

How does EVH drawdown profile look like?

EVH Financial Health

Current Ratio

1.01

Debt/Equity

0.56

Debt/Cashflow

0.24

EVH Investor Care

Shares Dilution (1Y)

13.61%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.5B1.6B1.8B2.0B
2022989.9M1.1B1.2B1.4B
2021918.5M923.2M906.1M908.0M
2020869.9M895.2M914.6M924.6M
2019685.1M732.8M803.0M846.4M
2018468.4M505.7M547.7M627.1M
2017311.0M361.5M409.2M434.9M
2016146.3M192.4M212.2M254.2M
201500096.9M
20140000
201300025.7M

Tracking the Latest Insider Buys and Sells of Evolent Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 05, 2023
blackley seth
sold
-3,741,480
26.5353
-141,000
chief executive officer
Dec 04, 2023
blackley seth
acquired
-
-
280,000
chief executive officer
Nov 15, 2023
mccarthy daniel joseph
sold
-330,000
30.00
-11,000
president
Nov 15, 2023
mccarthy daniel joseph
acquired
31,950
10.65
3,000
president
Oct 01, 2023
rafferty emily ann
sold (taxes)
-67,802
27.23
-2,490
chief operating officer
Aug 15, 2023
rafferty emily ann
sold
-221,595
28.05
-7,900
chief operating officer
Aug 01, 2023
shams aammaad
sold (taxes)
-66,515
30.4
-2,188
chief accounting officer
Aug 01, 2023
ajayi toyin
acquired
-
-
4,386
-
Jun 28, 2023
blackley seth
acquired
126,762
3.84
33,011
chief executive officer
Jun 28, 2023
blackley seth
sold
-1,016,020
30.7783
-33,011
chief executive officer

1–10 of 50

Which funds bought or sold EVH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
added
-
15,306,000
87,164,400
1.42%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
reduced
-43.88
-1,856,560
3,958,220
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
1.11
80,688
437,020
0.02%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
0.64
3,835,000
21,205,000
-%
Feb 15, 2024
Legal & General Group Plc
added
0.35
661,670
3,707,620
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
767
9,703,830
10,722,400
-%
Feb 15, 2024
Ilmarinen Mutual Pension Insurance Co
unchanged
-
568,000
3,237,000
0.04%
Feb 15, 2024
BARCLAYS PLC
added
97.95
4,959,000
8,498,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
1,751
1,751
-%
Feb 15, 2024
State of Wyoming
added
13.1
12,525
46,209
0.01%

1–10 of 38

Are Funds Buying or Selling EVH?

Are funds buying EVH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EVH
No. of Funds

Unveiling Evolent Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.41%
10,821,331
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
7.23%
8,313,157
SC 13G
Jan 26, 2024
blackrock inc.
7.3%
8,423,999
SC 13G/A
Jan 18, 2024
jpmorgan chase & co
5.1%
5,863,530
SC 13G/A
Apr 26, 2023
magellan health inc
0%
0
SC 13G/A
Apr 10, 2023
fmr llc
-
0
SC 13G
Mar 08, 2023
upmc
1.97%
2,190,702
SC 13G/A
Feb 14, 2023
granahan investment management, llc
3.12%
3,155,211
SC 13G/A
Feb 09, 2023
vanguard group inc
9.68%
9,790,816
SC 13G/A

Recent SEC filings of Evolent Health Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
S-3ASR
S-3ASR
Feb 23, 2024
10-K
Annual Report
Feb 22, 2024
8-K
Current Report
Feb 14, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
SC 13G
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 18, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report

Peers (Alternatives to Evolent Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
487.6B
360.0B
0.01% 5.90%
22.49
1.35
14.24% 11.62%
97.1B
357.8B
0.71% -14.01%
11.63
0.27
10.95% 93.52%
83.4B
65.0B
9.34% 20.24%
15.91
1.28
7.86% -7.11%
42.9B
154.0B
-0.09% 8.25%
15.86
0.28
6.54% 124.79%
11.3B
14.0B
2.25% 10.28%
16.73
0.81
6.03% -8.61%
11.0B
12.1B
12.03% 47.11%
15.88
0.9
4.57% 23.40%
MID-CAP
9.0B
2.2B
0.13% 16.69%
36.85
4.05
4.50% -6.69%
7.8B
2.9B
-3.46% 1.96%
-425.45
2.72
13.16% -106.47%
2.1B
3.8B
-19.95% -33.62%
9.84
0.55
-27.73% -52.50%
SMALL-CAP
2.4B
1.3B
4.99% 11.37%
53.3
1.79
27.06% -27.04%
1.4B
1.0B
8.40% -11.51%
25.01
1.4
10.84% 30.19%
994.0M
3.0B
7.30% 124.36%
-5.26
0.33
6.74% 20.73%
42.1M
-
-0.60% -54.62%
-2.91
-
- -27.68%
16.9M
20.7M
- -15.62%
83.48
0.82
6.53% -85.60%

Evolent Health Inc News

Latest updates
Yahoo Finance55 minutes ago
The Washington Post22 Feb 202410:11 pm

Evolent Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue8.8%556,055,000511,015,000469,136,000427,690,000382,432,000352,585,000319,939,000297,057,000248,358,000222,471,000222,057,000215,071,000246,536,000239,572,000217,299,000221,232,000236,525,000220,143,000191,959,000197,756,000193,104,000
Cost Of Revenue17.5%454,428,000386,585,000351,938,000310,475,000299,368,000266,617,000249,705,000219,739,000-------------
Costs and Expenses9.2%577,405,000528,953,000490,704,000438,045,000384,310,000339,634,000324,572,000299,855,000260,572,000229,052,000229,728,000----------
Operating Expenses--------299,855,000260,572,000229,052,000229,728,000231,016,000246,804,000256,020,000443,128,000246,323,000451,120,000240,281,000217,192,000244,402,000206,456,000
  S&GA Expenses-15.7%81,428,00096,567,00090,389,00089,726,00082,861,00068,521,00058,955,00058,932,00066,917,00051,292,00042,699,00058,591,00058,663,00052,366,00047,296,00052,087,00035,870,00058,808,00066,932,00074,838,00062,923,000
EBITDA Margin-777.6%-0.010.00-0.02-0.030.020.020.050.060.060.050.02-0.19---------
Interest Expenses-16.3%12,238,00014,614,00014,458,00012,895,0006,429,0004,754,0002,148,0002,241,0006,447,0006,367,0006,274,0006,337,0008,338,0007,416,0006,290,0006,281,0003,743,0003,630,0003,620,0003,562,0002,000,000
Income Taxes-164.7%-14,691,000-5,550,000-970,000-68,189,000-2,302,000-45,516,000-184,0001,202,000-453,000234,00091,000611,000763,000503,000-3,904,000270,000-22,848,000-849,0001,398,000-496,00011,000
Earnings Before Taxes-55.7%-48,067,000-30,874,000-35,293,000-88,171,000-10,227,000-43,393,000-4,309,000-4,148,0002,600,000-12,806,000-9,016,000-10,579,000-9,874,000-36,532,000-205,917,000-78,217,000-223,754,000-26,587,000-30,502,000-49,145,000-17,540,000
EBT Margin-12.1%-0.10-0.09-0.11-0.10-0.05-0.04-0.02-0.02-0.03-0.05-0.07-0.29---------
Net Income-31.9%-33,411,000-25,324,000-34,323,000-26,258,000-11,349,0002,123,000-4,588,000-5,350,000-5,647,000-13,040,000-9,107,000-9,807,000822,000-822,000---198,096,000-25,521,000-31,615,000-46,739,000-16,687,000
Net Income Margin-11.8%-0.06-0.05-0.04-0.03-0.01-0.01-0.03-0.03-0.04-0.03-0.02-0.01---------
Free Cashflow56.2%80,224,00051,364,000-8,503,000-17,131,00026,538,000-12,627,0004,507,000-66,599,00057,499,00035,344,000-33,404,000-57,320,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.4%2,6802,6702,6472,5891,8171,7591,3041,3391,4191,2541,2931,3061,3721,3921,2701,4511,4981,7141,6521,6291,722
  Current Assets7.0%684639577476478394423463524478506508548549275258229308241321488
    Cash Equivalents21.1%22318514315818815719321035528223830436237198.0068.0012997.0093.00171388
  Net PPE-2.1%78.0080.0084.0089.0088.0095.0093.0083.0081.0082.0083.0084.0086.0088.0089.0086.0085.0083.0080.0077.0074.00
  Goodwill-0.1%1,1171,1181,1181,11872372342642642677.00349349349349349570566772772770768
Liabilities2.6%1,4341,3981,3811,297958903691728726646679688752737623604569590506479533
  Current Liabilities9.6%674615541458433382343382445367403415403365245236193260173164269
  Short Term Borrowings-100.0%-1.00-------------------
  Long Term Debt-100.0%-600633632413412283283216211207202263285300297294228226223221
    LT Debt, Current----------27.0027.0027.0027.00--------
    LT Debt, Non Current-0.5%597600633632413412283283216211207202263---294----
Shareholder's Equity-2.6%1,0681,0961,0931,1228598566136116946076146176206556478479291,1241,1471,1501,189
  Retained Earnings-4.9%-719-685-660-626-606-594-596-592-626-621-608-598-589-574-537-333-251-53.87-28.343.0050.00
  Additional Paid-In Capital0.3%1,8081,8031,7751,7691,4871,4721,2311,2241,3411,2491,2431,2371,2291,2251,1841,1801,1741,1621,1581,0961,093
Shares Outstanding-100.0%-11211110894.0092.0090.0090.0086.0086.0085.0085.00---------
Minority Interest--------------25.00--7.0016.0016.0050.0046.00
Float-------2,500---1,600---540---600--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations47.7%89,38160,521654-7,97435,695-3,47013,664-57,44266,65644,501-24,247-48,163-12,851-20,49937,666-20,54113,187-16,590-13,533-25,709-24,968
  Share Based Compensation3.7%10,60310,2228,96610,71014,6316,9927,0125,3464,9574,3953,6533,7064,2313,1643,7033,5085735,7584,7504,5375,049
Cashflow From Investing1.5%-6,052-6,145-8,354-394,993-4,456-254,989-16,43616,766-54,368-1,798-5,57145,951-2,225281,679-7,575-10,807-79,174-11,644-65,338-25,478-135,442
Cashflow From Financing-125.7%-84,352-37,36723,330379,729-10,854173,08120,690-51,37660,898641-35,503-55,584-23,916-13,856-6,66432,574-11,24696,772-11,406-109,665281,959
  Buy Backs---------------685------

EVH Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue[1]$ 511,015$ 352,585$ 1,407,841$ 969,581
Expenses    
Cost of revenue[1]386,585266,6171,048,998736,061
Selling, general and administrative expenses[1]96,56768,521276,682186,408
Depreciation and amortization expenses32,40417,19693,81347,414
Loss on disposal of assets2,09702,0970
Right-of-use assets impairment0024,0650
Change in fair value of contingent consideration11,300(12,700)12,047(5,822)
Total operating expenses528,953339,6341,457,702964,061
Operating income (loss)(17,938)12,951(49,861)5,520
Interest income1,0714252,735765
Interest expense(14,614)(4,754)(41,967)(9,143)
Gain from equity method investees6841,3921,2623,940
Loss on repayment on long-term debt, net0(10,192)0(10,192)
Change in tax receivables agreement liability0(42,870)(66,184)(42,870)
Other income (expense), net(77)(345)(323)130
Loss before income taxes(30,874)(43,393)(154,338)(51,850)
Benefit from income taxes(5,550)(45,516)(74,709)(44,498)
Income (loss) from continuing operations(25,324)2,123(79,629)(7,352)
Loss from discontinued operations, net of tax[2]000(463)
Income (loss) before preferred dividends and accretion of Series A Preferred Stock(25,324)2,123(79,629)(7,815)
Dividends and accretion of Series A Preferred Stock(7,872)0(21,236)0
Net income (loss) attributable to common shareholders of Evolent Health, Inc. - Basic(33,196)2,123(100,865)(7,815)
Net income (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted$ (33,196)$ 2,123$ (100,865)$ (7,815)
Basic:    
Continuing operations (in dollars per share)$ (0.30)$ 0.02$ (0.91)$ (0.08)
Discontinued operations (in dollars per share)000(0.01)
Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc, (in dollars per share)(0.30)0.02(0.91)(0.09)
Diluted:    
Continuing operations (in dollars per share)(0.30)0.02(0.91)(0.08)
Discontinued operations (in dollars per share)000(0.01)
Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc, (in dollars per share)$ (0.30)$ 0.02$ (0.91)$ (0.09)
Weighted-average common shares outstanding    
Basic (in shares)112,28295,286110,46491,643
Diluted (in shares)112,28299,308110,46491,643
Comprehensive income (loss)    
Net income (loss) attributable to common shareholders of Evolent Health, Inc.$ (33,196)$ 2,123$ (100,865)$ (7,815)
Other comprehensive income (loss), net of taxes, related to:    
Foreign currency translation adjustment(151)(262)(87)(682)
Total comprehensive income (loss) attributable to common shareholders of Evolent Health, Inc.$ (33,347)$ 1,861$ (100,952)$ (8,497)
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.
[2]Includes $(0.5) million loss on disposal for of discontinued operations for the nine months ended September 30, 2022.

EVH Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 184,536$ 188,200
Restricted cash and restricted investments23,20814,492
Accounts receivable, net[1]394,232254,684
Prepaid expenses and other current assets[1]36,82220,678
Total current assets638,798478,054
Restricted cash and restricted investments16,75412,466
Investments in equity method investees4,8674,475
Property and equipment, net79,90287,874
Right-of-use assets - operating17,40649,027
Prepaid expenses and other noncurrent assets[1]3,2642,378
Contract cost assets13,41317,461
Intangible assets, net777,668442,784
Goodwill1,117,543722,774
Total assets2,669,6151,817,293
Current liabilities:  
Accounts payable[1]51,77657,174
Accrued liabilities[1]193,961111,198
Operating lease liability - current12,9667,122
Accrued compensation and employee benefits50,09552,460
Deferred revenue5,7635,758
Short-term debt, net9910
Reserve for claims and performance - based arrangements299,742199,730
Total current liabilities615,294433,442
Long-term debt, net599,947412,986
Other long-term liabilities3,9784,744
Tax receivables agreement liability112,13445,950
Operating lease liabilities - noncurrent39,65056,010
Deferred tax liabilities, net26,9134,744
Total liabilities1,397,916957,876
Commitments and Contingencies (See Note 10)
Mezzanine Equity  
Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 and 0 shares issued, respectively175,6060
Shareholders' Equity  
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 114,789,963 and 101,500,558 shares issued, respectively1,1481,015
Additional paid-in-capital1,803,1161,486,857
Accumulated other comprehensive loss(1,265)(1,178)
Retained earnings (accumulated deficit)(685,783)(606,154)
Treasury stock, at cost; 1,537,582 shares issued, respectively(21,123)(21,123)
Total shareholders' equity1,096,093859,417
Total liabilities, mezzanine equity and shareholders' equity$ 2,669,615$ 1,817,293
[1]See Note 18 for amounts attributable to related parties included in these line items.
EVH
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology, cardiology, and musculoskeletal markets; physician-oriented total cost of care solutions; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
 CEO
 WEBSITEwww.evolenthealth.com
 EMPLOYEES5100

Evolent Health Inc Frequently Asked Questions


What is the ticker symbol for Evolent Health Inc? What does EVH stand for in stocks?

EVH is the stock ticker symbol of Evolent Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evolent Health Inc (EVH)?

As of Fri Feb 23 2024, market cap of Evolent Health Inc is 3.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers. The fair value of Evolent Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evolent Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evolent Health Inc a good stock to buy?

The fair value guage provides a quick view whether EVH is over valued or under valued. Whether Evolent Health Inc is cheap or expensive depends on the assumptions which impact Evolent Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVH.

What is Evolent Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, EVH's PE ratio (Price to Earnings) is -40.26 and Price to Sales (PS) ratio is 2.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVH PE ratio will change depending on the future growth rate expectations of investors.